RxDoctor Payments Data

Patricia Hodgins, MD

Surgery · Fenton, MONPI 1457791808

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (54.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 99.2% of it on its own, with 9 other manufacturers making up the rest. Among surgery clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$144,595in general payments, 2019–2025

Across 320 payments — averaging $451.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$143K
  • Endo Pharmaceuticals Inc.$402
  • Neotract Inc.$243
  • Calyxo, Inc.$165
  • Astellas Pharma US Inc$121
  • Convatec Inc.$69
  • plus $120 from 4 others

What the payments were for

  • Consulting fees$43,95030%
  • Speaking & faculty fees$78,71554%
  • Travel & lodging$12,3519%
  • Food & beverage$9,3336%
  • Education$2470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$144,595 in reported general payments places this provider in the 95th percentile of 612 surgery providers in Missouri.

See all surgery providers in Missouri

Medicare billing

Part B allowed, 2024
$261,764
Medicare patients
485
Services billed
3,929

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron110$63,008
GemtesaVibegron17$14,098
Tamsulosin Hcl813$11,715
Mirabegron ErMirabegron22$11,377
Testosterone40$6,589
Trospium Chloride ErTrospium Chloride19$5,426
Potassium Citrate ErPotassium Citrate38$4,151
Alfuzosin Hcl ErAlfuzosin Hcl277$3,938
Solifenacin Succinate109$3,814
Finasteride316$3,425
Testosterone Cypionate103$3,217
Estradiol23$3,145
Silodosin23$1,926
Methenamine Hippurate20$1,661
Oxybutynin Chloride ErOxybutynin Chloride37$1,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$121$63,008110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 612 surgery providers in Missouri.

Other surgery in Fenton

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →